Japanese guidance for use of biologics for psoriasis (the 2013 version)
- 5 September 2013
- journal article
- practice guideline
- Published by Wiley in The Journal of Dermatology
- Vol. 40 (9) , 683-695
Abstract
The clinical use of adalimumab and infliximab, human anti‐tumor necrosis factor (TNF)‐α monoclonal antibodies, for psoriasis began in January 2010. In January 2011, ustekinumab, a human anti‐interleukin‐12/23p40 (IL‐12/23p40) monoclonal antibody, was newly approved as the third biologic with an indication for psoriasis. While all of these biologics are expected to exhibit excellent therapeutic effect for psoriasis and to contribute to the improvement of quality of life in patients, these drugs require careful safety measures to prevent adverse drug reactions, such as serious infections. The new guidance, an English version prepared by revising the Japanese Guidance/Safety Manual for Use of Biologics for Psoriasis 2011 (in Japanese), is intended to provide up‐to‐date, evidence‐based recommendations and safety measures on the use of biologics, and describes the optimal use of the three biologics, medical requirements for facilities for using biologics, details of safety measures against reactivation of tuberculosis and hepatitis B virus infection, and recommendable combination therapies with biologics.Keywords
This publication has 12 references indexed in Scilit:
- S3 – Guidelines on the treatment of psoriasis vulgaris (English version). UpdateJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2012
- Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trialThe Journal of Dermatology, 2011
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2011
- Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trialJournal of Dermatological Science, 2010
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled studyThe Journal of Dermatology, 2010
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- European S3‐Guidelines on the systemic treatment of psoriasis vulgarisJournal of the European Academy of Dermatology and Venereology, 2009
- Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral HepatitisKanzo, 2009
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2008
- Current severe psoriasis and the Rule of TensBritish Journal of Dermatology, 2005